Here, we demonstrated that apart from inhibiting neuroinflammation, fluoxetine could restore HDAC1-eEF2 activity (phosphorylation), which eventually reversed synaptogenic loss and depression-like phenotypes. The gene discussed is HDAC1; the disease is depressive disorder.